

Primary disease: 977 (868 C2/3 disease)
patients, 1252 limbs
Recurrent disease:
372 patients
GSV (n ¼ 286) SSV (n ¼ 50)
AASV (n ¼ 46)

FS

none

Prospective
No signiﬁcant
difference in
retreatment rates
between UGFS for GSV
and SSV re